GASTRIC CANCER
Clinical trials for GASTRIC CANCER explained in plain language.
Never miss a new study
Get alerted when new GASTRIC CANCER trials appear
Sign up with your email to follow new studies for GASTRIC CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New weapon tested against Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new drug called SAR443216 in people with advanced solid tumors that have a protein called HER2 and have stopped responding to other treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked…
Matched conditions: GASTRIC CANCER
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
First human test of Pfizer's new cancer drug halted early
Disease control TerminatedThis was an early-stage study to test the safety and find the right dose of a new cancer drug called PF-07265028. It was given alone and in combination with another immunotherapy drug, sasanlimab, to a small group of people with advanced solid tumors that had stopped responding t…
Matched conditions: GASTRIC CANCER
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Experimental drug tested for Tough-to-Treat cancers
Disease control TerminatedThis study tested an experimental drug called VLS-101 (zilovertamab vedotin) in 102 people with advanced solid tumors that had spread and stopped responding to previous treatments. The trial aimed to see if the drug could shrink tumors and was safe for cancers including breast, l…
Matched conditions: GASTRIC CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New cancer drug trial halted early
Disease control TerminatedThis early-stage study aimed to test the safety and find the right dose of a new drug called BLU-222 for people with advanced solid tumors that have stopped responding to standard treatments. It involved about 50 patients with cancers like breast, ovarian, and gastric cancer. The…
Matched conditions: GASTRIC CANCER
Phase: PHASE1 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New pill tested as potential lifeline for Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specif…
Matched conditions: GASTRIC CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New cancer drug trial halted after early testing
Disease control TerminatedThis early-stage study tested a new drug called OC-001, both by itself and combined with an existing immunotherapy drug, in people with various advanced cancers that had stopped responding to standard treatments. The main goal was to check the safety of the drug and see how the b…
Matched conditions: GASTRIC CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New drug combo tested in fight against advanced stomach cancer
Disease control TerminatedThis study tested whether adding an experimental drug called DKN-01 to a standard immunotherapy (tislelizumab) and chemotherapy could better control advanced stomach or gastroesophageal cancer. It involved about 247 adults whose cancer could not be removed by surgery. The main go…
Matched conditions: GASTRIC CANCER
Phase: PHASE2 • Sponsor: Leap Therapeutics, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New cancer drug trial tests immune system booster for tough tumors
Disease control TerminatedThis study tested a new drug called TAK-500, designed to activate the immune system to fight cancer. It was given alone or combined with an existing immunotherapy drug (pembrolizumab) to adults with advanced solid tumors that had stopped responding to standard treatments. The mai…
Matched conditions: GASTRIC CANCER
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC